Reaction

Bladder Pain reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,115 reports · 80 co-occurring drugs

As of the last recalculation, Bladder Pain appears in 3,115 FAERS reports alongside 80 co-occurring drug terms. The strongest observed disproportionality signal is VIBEGRON (PRR 22.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Vibegron	27	22.7	22.8
Fesoterodine Fumarate	33	20.6	20.6
Diltiazem Hydrochloride Extended-Release Tablets	33	19.6	19.6
Mirabegron	87	15.4	15.5
Mometasone	34	12.5	12.5
Oxybutynin	43	9.9	10.0
Theophylline	16	9.3	9.4
Theophylline Anhydrous	17	9.2	9.2
Ciprofloxacin Hydrochloride And Hydrocortisone	25	8.1	8.1
Diltiazem Hydrochloride	40	7.8	7.8
Cephalexin	25	7.8	7.8
Ciprofloxacin Hydrochloride	104	7.4	7.4
Ciprofloxacin	97	7.3	7.3
Omalizumab	89	7.2	7.2
Ciprofolxacin	73	7.0	7.0
Ciprofloxacin Tablets	73	7.0	7.0
Metformin Hydrochloride Tablets	58	6.9	6.9
Metformin Hydrochloride Extended-Release Tablets	58	6.9	6.9
Metformin Hydrochloride Tablet	58	6.9	6.9
Metformin Hydrochloride	59	6.8	6.8
Mometasone Furoate	39	6.3	6.3
Zinc	23	6.3	6.3
Zinc Chloride	23	6.2	6.2
Tolterodine Tartrate	8	6.0	6.0
Zinc Gluconate	23	5.9	5.9
Meperidine Hydrochloride	8	5.8	5.8
Atorvastatin Calcium, Film Coated	59	5.7	5.7
Clonazepam	131	5.7	5.7
Nitrofurantoin (Monohydrate/Macrocrystals)	12	4.8	4.8
Dicyclomine Hydrochloride	10	4.7	4.7
Rucaparib	6	4.5	4.5
Estradiol	56	4.4	4.4
Piperacillin Sodium,Tazobactam Sodium	17	4.3	4.3
Lisinopril And Hydrochlorothiazide Tablets	5	4.3	4.3
Piperacillin And Tazobactam	8	4.2	4.2
Esketamine Hydrochloride	11	4.1	4.1
Dutasteride	5	4.1	4.1
Progesterone	14	4.1	4.1
Lisinopril And Hydrochlorothiazide	6	3.9	3.9
Isosorbide Mononitrate	12	3.9	3.9
Polyethylene Glycol 400	7	3.7	3.7
Conjugated Estrogens	31	3.6	3.6
Estrogens, Conjugated	31	3.5	3.5
Relugolix	12	3.4	3.4
Dronedarone	5	3.3	3.3
Botulinum Toxin Type A	6	3.2	3.2
Ozanimod Hydrochloride	4	3.2	3.2
Acetaminophen, Aspirin (Nsaid) And Caffeine	8	3.1	3.1
Asenapine Maleate	4	3.1	3.1
Onabotulinumtoxina	35	3.1	3.1
Leuprolide Acetate	35	3.0	3.0
Acetaminophen, Aspirin, And Caffeine	9	2.9	2.9
Insulin Degludec	10	2.9	2.9
Umeclidinium Bromide And Vilanterol Trifenatate	7	2.8	2.8
Belimumab	13	2.8	2.8
Liraglutide	20	2.7	2.7
Alirocumab	10	2.7	2.7
Prasugrel Hydrochloride	4	2.6	2.6
Loratadine And Pseudoephedrine Sulfate	3	2.5	2.5
Inclisiran	3	2.5	2.5
Droxidopa	8	2.5	2.5
Abiraterone	5	2.5	2.5
Interferon Beta-1B	7	2.4	2.4
Fingolimod Hcl	30	2.3	2.3
Enzalutamide	20	2.3	2.3
Canagliflozin	10	2.2	2.2
Gefitinib	3	2.2	2.2
Cariprazine	3	2.2	2.2
Dalfampridine	23	2.2	2.2
Teriparatide	34	2.0	2.0
Rimegepant Sulfate	3	1.6	1.6
Orlistat	6	1.5	1.5
Abiraterone Acetate	9	1.5	1.5
Sarilumab	5	1.3	1.3
Levonorgestrel	34	1.1	1.1
Galcanezumab-Gnlm	5	1.1	1.1
Tapentadol Hydrochloride	5	1.0	1.0
Evolocumab	24	1.0	1.0
Pirfenidone	6	1.0	1.0
Copper	4	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.